Regeneron has filed a lawsuit against Sandoz following the recent approval of Sandoz's aflibercept biosimilar in the US. The lawsuit, filed under the Biologics Price Competition and Innovation Act (BPCIA), comes just days after the biosimilar received regulatory approval. This legal action highlights the ongoing tensions in the pharmaceutical industry regarding biosimilar products and patent rights.